Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 5 2 2011 06 15 34 37 Mehrdad Payande Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Mohammad Erfan Zare Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Saber Ghanbari Haji Shure Student of Medical Lab Sciences in Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran Farhad Shaveisi Zadeh Medical Genetics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences and Heaith Services, Tehran, Iran 2015 10 01 Myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, primary myelofibrosis and chronic myeloid leukemia have too similar and accurate way to differentiate their is study of genetic disorders in these patients. Philadelphia chromosome is a sure way to definitively diagnose CML. Recently, JAK2V617F mutation introduced as a diagnostic marker for other Myeloproliferative neoplasms. Many studies show that the absence of the JAK2 mutation in chronic phase Philadelphia positive CML. In contrast with these reports, more recently, several cases with the coexistence of Philadelphia positive chromosome and JAK2V617F mutation in blood and bone marrow samples were reported. Here, we report a patient that have the Philadelphia chromosome disorder and JAK2V617F mutation in same time. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/278 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/278/271